| A need to revisit clinical breakpoints of tigecycline: effect of atypical non-linear plasma protein binding RSP Singh, JK Mukker, SK Drescher, AN Deitchman, H Derendorf International journal of antimicrobial agents 49 (4), 449-455, 2017 | 18 | 2017 |
| Can pharmacokinetic studies assess the pulmonary fate of dry powder inhaler formulations of fluticasone propionate? G Hochhaus, MJ Chen, A Kurumaddali, U Schilling, Y Jiao, SK Drescher, ... The AAPS journal 23, 1-14, 2021 | 17 | 2021 |
| Four decades of β-lactam antibiotic pharmacokinetics in cystic fibrosis JB Bulitta, Y Jiao, SK Drescher, A Oliver, A Louie, B Moya, X Tao, ... Clinical Pharmacokinetics 58, 143-156, 2019 | 15 | 2019 |
| Role of divalent metal ions in atypical nonlinear plasma protein binding behavior of tigecycline RSP Singh, JK Mukker, AN Deitchman, SK Drescher, H Derendorf Journal of Pharmaceutical Sciences 105 (11), 3409-3414, 2016 | 14 | 2016 |
| Oncology dose optimization paradigms: knowledge gained and extrapolated from approved oncology therapeutics RK Mittapalli, C Guo, SK Drescher, D Yin Cancer Chemotherapy and Pharmacology 90 (3), 207-216, 2022 | 8 | 2022 |
| First population pharmacokinetic analysis showing increased quinolone metabolite formation and clearance in patients with cystic fibrosis compared to healthy volunteers Y Jiao, TH Kim, X Tao, M Kinzig, CB Landersdorfer, SK Drescher, ... European Journal of Pharmaceutical Sciences 123, 416-428, 2018 | 8 | 2018 |
| Unraveling the pulmonary fate of fluticasone and friends: meeting the physiologic and pharmacokinetic challenges G Hochhaus, M Chen, J Shur, A Kurumaddali, U Schilling, Y Jiao, ... Respir Drug Deliv 2020, 139-146, 2020 | 5 | 2020 |
| A phase 1, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of PF-07799933 (ARRY-440) as a … JTT Beck, M McKean, SM Gadgeel, DW Bowles, R Haq, R Yaeger, ... Journal of Clinical Oncology 41 (16_suppl), TPS3164-TPS3164, 2023 | 3 | 2023 |
| Central and peripheral lung deposition of fluticasone propionate dry powder inhaler formulations in humans characterized by population pharmacokinetics SK Drescher, Y Jiao, MJ Chen, A Kurumaddali, J Shao, E Amini, ... Pharmaceutical research 40 (5), 1177-1191, 2023 | 2 | 2023 |
| Pharmacokinetics and pharmacodynamics of drugs delivered to the lung SK Drescher, MJ Chen, JB Bulitta, G Hochhaus Pharmaceutical Inhalation Aerosol Technology, Third Edition, 131-178, 2019 | 2 | 2019 |
| A next-generation BRAF inhibitor overcomes resistance to BRAF inhibition in patients with BRAF-mutant cancers using pharmacokinetics-informed dose escalation R Yaeger, MA McKean, R Haq, JT Beck, MH Taylor, JE Cohen, ... Cancer Discovery, 2024 | | 2024 |
| Abstract CT178: Phase 1 trial of PF-07799933 (ARRY-440), a next-generation BRAF inhibitor, for BRAF-mutant cancers R Yaeger, M McKean, R Haq, JT Beck, MH Taylor, J Cohen, D Bowles, ... Cancer Research 84 (7_Supplement), CT178-CT178, 2024 | | 2024 |
| Sensitivity of Pharmacokinetics to Differences in the Particle Size Distribution for Formulations of Locally Acting Mometasone Furoate Suspension-Based Nasal Sprays E Amini, SM Berger, U Schilling, Y Jiao, MJ Chen, S Bachhav, ... Molecular Pharmaceutics 20 (11), 5690-5700, 2023 | | 2023 |
| Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate?(vol 23, 48, 2021) G Hochhaus, MJ Chen, A Kurumaddali, U Schilling, Y Jiao, SK Drescher, ... AAPS JOURNAL 24 (1), 2021 | | 2021 |
| Correction to: Can Pharmacokinetic Studies Assess the Pulmonary Fate of Dry Powder Inhaler Formulations of Fluticasone Propionate? G Hochhaus, MJ Chen, A Kurumaddali, U Schilling, Y Jiao, SK Drescher, ... The AAPS journal 24 (1), 1, 2021 | | 2021 |
| Evaluating the Pulmonary Fate of Inhaled Therapeutics via Computational Modeling SK Drescher University of Florida, 2020 | | 2020 |
| Assessing Central and Peripheral Pulmonary Deposition of Three Fluticasone Propionate (FP) Dry Powder Inhaler (DPI) Formulations with Different Aerodynamic Particle Size … SK Drescher, MJ Chen, A Kurumaddali, U Schilling, Y Jiao, J Shao, ... JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY 32 (2), A10-A10, 2019 | | 2019 |
| Receptor binding informed QSP modeling to design and rationally optimize synergistic, oral double beta-lactam combination therapy against resistant Escherichia coli Y Jiao, X Tao, B Moya, DS Sutaria, SK Drescher, JB Bulitta JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 45, S122-S123, 2018 | | 2018 |
| THE EFFECT OF PROTEIN BINDING ON THE BREAKPOINT FOR ANTIBIOTICS. SK Drescher, D Tenero, D Austin, J Hoover, N Goyal CLINICAL PHARMACOLOGY & THERAPEUTICS 103, S30-S30, 2018 | | 2018 |
| A Pharmacodynamic driven model which incorporated the correlation of pulmonary and cardiac effects of fenoterol in asthmatic patients after different routes of administration D Stefanie, B Jurgen, H Gunther JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS 44, S38-S38, 2017 | | 2017 |
